SG11201810934TA - Microparticles comprising a sulphur-containing compound - Google Patents

Microparticles comprising a sulphur-containing compound

Info

Publication number
SG11201810934TA
SG11201810934TA SG11201810934TA SG11201810934TA SG11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA
Authority
SG
Singapore
Prior art keywords
international
aberdeen
microparticles
june
pct
Prior art date
Application number
SG11201810934TA
Inventor
Deborah O'neil
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of SG11201810934TA publication Critical patent/SG11201810934TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT IiiimmomiolollmolommiolomomolomillomovoimIE (10) International Publication Number WO 2017/212249 Al (51) International Patent Classification: A61K 31/145 (2006.01) A61K 45/06 (2006.01) A61K 9/00 (2006.01) A61P 11/00 (2006.01) A61K 9/16 (2006.01) (21) International Application Number: PCT/GB2017/051637 (22) International Filing Date: 06 June 2017 (06.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/346,969 07 June 2016 (07.06.2016) US 1609940.0 07 June 2016 (07.06.2016) GB (71) Applicant: NOVABIOTICS LIMITED [GB/GB]; Cruickshank Building, Craibstone, Aberdeen Aberdeen- shire AB21 9TR (GB). (72) Inventor: O'NEIL, Deborah; Novabiotics Limited, Cruickshank Building, Craibstone, Aberdeen Aberdeen- shire AB21 9TR (GB). (74) Agent: HARRISON IP LIMITED; 3 Ebor House, Mill- field Lane, Nether Poppleton, York Yorkshire Y026 6QY (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: MICROPARTICLES COMPRISING A SULPHUR-CONTAINING COMPOUND Figure 1 1.4 cr c 12 0 1.0 it) 0.8 't! 0.6 \"Zei 0.4 1-1 0,1 0.5 71' (57) : The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a © pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing N agent. C [Continued on next page] 5 10 particle size I prn * at; a .fie a *446 wousj 50 100 500 WO 2017/212249 Al DIII Published: — with international search report (Art. 21(3))
SG11201810934TA 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound SG11201810934TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (1)

Publication Number Publication Date
SG11201810934TA true SG11201810934TA (en) 2019-01-30

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810934TA SG11201810934TA (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Country Status (16)

Country Link
US (1) US11369568B2 (en)
EP (1) EP3463325B1 (en)
JP (1) JP7195934B2 (en)
KR (1) KR102412212B1 (en)
CN (1) CN109310654A (en)
AU (1) AU2017277897B2 (en)
BR (1) BR112018075221B1 (en)
CA (2) CA3026743A1 (en)
DK (1) DK3463325T3 (en)
ES (1) ES2965017T3 (en)
FI (1) FI3463325T3 (en)
GB (1) GB201609940D0 (en)
MX (1) MX2018014278A (en)
SG (1) SG11201810934TA (en)
WO (1) WO2017212249A1 (en)
ZA (1) ZA201807852B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
AU2019360638A1 (en) * 2018-10-17 2021-06-03 Novabiotics Limited Dosage regime
CN116171149A (en) * 2020-09-03 2023-05-26 菲利普莫里斯生产公司 Spray-dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (en) * 1989-05-02 1989-05-02 Draco Ab ORGANIC SALTS OF CYSTEINE DERIVATIVES
CN101094651B (en) 2004-12-30 2011-03-09 多贝尔有限公司 Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
AR057623A1 (en) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd MATERIALS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
EP2094236A1 (en) 2006-12-22 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (en) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 (R,R)-formoterol inhalation dust cloud agent and preparation method thereof
JP2012509922A (en) * 2008-11-27 2012-04-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New powdered crystalline inhalant
US8389021B2 (en) 2009-02-03 2013-03-05 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CA2981038C (en) 2011-05-19 2018-09-25 Savara Inc. Dry powder vancomycin compositions and associated methods
JP5981123B2 (en) 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク Method for producing nicotine drug and pharmaceutical produced by the method
US9468612B2 (en) * 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
SG11201404779TA (en) * 2012-02-10 2014-09-26 Whitehead Biomedical Inst Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (en) * 2013-04-10 2014-10-11 Eratech Srl COMPOSITION INCLUDING AT LEAST TWO DRIED POWDERS OBTAINED FOR DRY SPRAYS TO INCREASE THE STABILITY OF THE FORMULATION
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (en) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE INCLUDING CISTEAMINE OR ITS SALT
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Also Published As

Publication number Publication date
CA3096121A1 (en) 2017-12-14
RU2018142841A (en) 2020-06-04
EP3463325B1 (en) 2023-11-08
CA3096121C (en) 2022-11-15
ZA201807852B (en) 2023-05-31
ES2965017T3 (en) 2024-04-10
DK3463325T3 (en) 2024-01-02
AU2017277897A1 (en) 2018-12-20
JP7195934B2 (en) 2022-12-26
CA3026743A1 (en) 2017-12-14
FI3463325T3 (en) 2023-12-19
KR102412212B1 (en) 2022-06-23
MX2018014278A (en) 2019-03-14
JP2019517541A (en) 2019-06-24
BR112018075221B1 (en) 2024-02-06
BR112018075221A2 (en) 2019-03-19
GB201609940D0 (en) 2016-07-20
AU2017277897B2 (en) 2022-09-08
US11369568B2 (en) 2022-06-28
RU2018142841A3 (en) 2020-09-30
WO2017212249A1 (en) 2017-12-14
EP3463325A1 (en) 2019-04-10
KR20190016957A (en) 2019-02-19
CN109310654A (en) 2019-02-05
US20190175501A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201909949XA (en) Targeted immunotolerance
SG11201804915RA (en) Methods for treating huntington&#39;s disease
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201805072PA (en) Nicotine powder delivery system
SG11201803906PA (en) Control of cellular redox levels
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809594WA (en) Nicotine particles and compositions
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805204WA (en) Nicotine particle capsule
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201809882XA (en) Pharmaceutical combinations for treating cancer